0HTB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Statistically Significant HOPE-3 Primary EndpointThe statistically significant HOPE-3 primary outcome provides clinical evidence for deramiocel’s potential to preserve upper-limb function in DMD. If validated through regulatory review, this differentiated efficacy could support approval, patient adoption, and a durable position in a rare-disease market.
Peer-reviewed Clinical ValidationPublication of the full Phase 3 dataset in The Lancet strengthens the program’s scientific credibility and gives regulators, physicians, and potential partners access to independently scrutinized evidence. This improves the foundation for future commercialization and broader clinical acceptance.
Meaningful Cash Resources And Operational ReadinessThe $237.9 million cash and securities balance gives Capricor resources to continue regulatory work and prepare for a potential launch. Operational in-house GMP capability also provides a direct manufacturing base, supporting execution if deramiocel receives approval.
Bears Say
FDA Review Delay And Adverse Advisory VoteThe three-month FDA review extension delays potential commercial entry, while the 3–9 advisory vote materially weakens confidence in the originally requested cardiomyopathy indication. The major amendment also signals that additional review and regulatory execution remain necessary.
Persistent Cash Burn And Funding DependenceNegative operating and free cash flow across every reported period means Capricor is not funding operations through its business. Continued development and launch preparation therefore depend on existing cash and future financing, limiting flexibility if approval or commercialization takes longer.
No Commercial Revenue With Widening LossesThe absence of product revenue alongside sharply higher operating expenses and a widening net loss shows that Capricor has not yet established commercial scale. Until a candidate is approved and launched, financial performance will remain highly dependent on funding rather than recurring customer sales.
Capricor Therapeutics News
0HTB FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is €477.38M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 54 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.6 earnings per share for the quarter, missing the consensus estimate of -€0.505 by -€0.095.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 58,138,990 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -€0.6 in its last earnings report, missing expectations of -€0.505. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in GB:0HTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€23.56 (― Upside)
€23.56 (― Upside)
Blogger Sentiment
Bullish
GB:0HTB Sentiment 82%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
0HTB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful clinical and regulatory progress (Lancet publication, statistically significant primary HOPE‑3 endpoint for upper limb function, established safety exposure, operational in‑house manufacturing and $237.9M cash) against substantial near‑term challenges (AdCom vote against the cardiomyopathy question, mixed secondary endpoint results, no revenue, rising operating expenses and widening losses, a Form 483 observation, paused non‑Daramycin pipeline work, and an ongoing commercial dispute with NS Pharma). Management has a clear path to submit an amendment focused on the primary skeletal muscle indication and the FDA indicated willingness to review it, but regulatory and financial risks remain in the near term.View all GB:0HTB earnings summaries